1h Free Analyst Time
Abcam Plc (ABC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.Speak directly to the analyst to clarify any post sales queries you may have.
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Abcam Plc (Abcam) is a supplier of life science research tools for analysis of living cells at molecular level to understand a wide range of disease conditions. The company develops and markets antibodies and other related products. Its product portfolio includes primary antibodies, secondary antibodies, immunoassay kits and reagents, cell and tissue imaging tools, cellular and biochemical assays, proteins and peptides, proteomics tools, activators, agonists, antagonists and inhibitors, lysates, and multiplex miRNA assay. Abcam’s products serve life science researchers to identify proteins for life sciences and veterinary sciences. The company distributes its products in the Americas, Europe, Asia-Pacific, and other countries. Abcam is headquartered in Cambridge, Cambridgeshire, the UK.Abcam Plc Key Recent Developments
Nov 09, 2022: NanoString and Abcam expand collaboration to advance spatial multiomics researchSep 12, 2022: ABCAM : Appointment of Non-Executive Director
Sep 01, 2022: Abcam to participate in the Morgan Stanley 20th Annual Global Healthcare Conference
Apr 04, 2022: ABCAM Announces Publication of 2021 Annual Report and Accounts and Notice of Annual General Meeting
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Section 1 - About the Company- Abcam Plc - Key Facts
- Abcam Plc - Key Employees
- Abcam Plc - Key Employee Biographies
- Abcam Plc - Major Products and Services
- Abcam Plc - History
- Abcam Plc - Company Statement
- Abcam Plc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Company Overview
- Abcam Plc - Business Description
- Other Break-up: BioVision
- Performance
- Other Break-up: Catalogue Product
- Overview
- Performance
- Other Break-up: Custom Products and Licensing
- Overview
- Performance
- Geographical Segment: China
- Performance
- Geographical Segment: EMEA
- Performance
- Geographical Segment: Japan
- Performance
- Geographical Segment: Rest of Asia Pacific
- Performance
- Geographical Segment: The Americas
- Performance
- R&D Overview
- Abcam Plc - Corporate Strategy
- Abcam Plc - SWOT Analysis
- SWOT Analysis - Overview
- Abcam Plc - Strengths
- Abcam Plc - Weaknesses
- Abcam Plc - Opportunities
- Abcam Plc - Threats
- Abcam Plc - Key Competitors
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Abcam Plc, Medical Equipment, Deals By Year, 2017 to YTD 2023
- Abcam Plc, Medical Equipment, Deals By Type, 2017 to YTD 2023
- Abcam Plc, Recent Deals Summary
- Nov 09, 2022: NanoString and Abcam expand collaboration to advance spatial multiomics research
- Sep 12, 2022: ABCAM : Appointment of Non-Executive Director
- Sep 01, 2022: Abcam to participate in the Morgan Stanley 20th Annual Global Healthcare Conference
- Apr 04, 2022: ABCAM Announces Publication of 2021 Annual Report and Accounts and Notice of Annual General Meeting
- Mar 25, 2022: Abcam the most awarded company at 2022 industry awards
- Mar 14, 2022: Abcam: Results for the period ended 31 December 2021
- Jan 04, 2022: Alamar Biosciences partners with Abcam to drive understanding of the human proteome
- Methodology
- Ratio Definitions
- About the Publisher
- Contact the Publisher
- Disclaimer
- Abcam Plc, Key Facts
- Abcam Plc, Key Employees
- Abcam Plc, Key Employee Biographies
- Abcam Plc, Major Products and Services
- Abcam Plc, History
- Abcam Plc, Subsidiaries
- Abcam Plc, Key Competitors
- Abcam Plc, Ratios based on current share price
- Abcam Plc, Annual Ratios
- Abcam Plc, Interim Ratios
- Abcam Plc, Medical Equipment, Deals By Year, 2017 to YTD 2023
- Abcam Plc, Medical Equipment, Deals By Type, 2017 to YTD 2023
- Abcam Plc, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- Abcam Plc, Performance Chart (2017 - 2021)
- Abcam Plc, Ratio Charts
- Abcam Plc, Medical Equipment, Deals By Year, 2017 to YTD 2023
- Abcam Plc, Medical Equipment, Deals by Type, 2017 to YTD 2023
Companies Mentioned
A selection of companies mentioned in this report includes:
- bioMerieux SA
- Illumina Inc
- Beckman Coulter Inc
- Siemens Healthineers AG
- F. Hoffmann-La Roche Ltd